查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138413

全球痛風藥物市場-2022-2029

Global Gout Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球痛風藥物市場的增長歸因於生活方式的改變、飲酒量的增加、肥胖和腎臟疾病的增加、高嘌呤飲食，以及由於多種藥物利尿劑導致痛風在世界範圍內的流行。市場增長的主要動力之一。

在預測期內，生物製劑的日益普及和再生醫學研發的增加預計將推動全球痛風治療市場。

推動市場增長的主要因素是越來越多地採用生物製劑和增加再生醫學的研發，以及提高診斷成像模式的技術進步。這種情況可以通過使用非甾體抗炎藥、皮質類固醇、秋水仙鹼和降尿酸劑等藥物來治療或預防。

生物製劑正在迅速普及，並正在以更有效的方式取代 NSAID 和皮質類固醇。因此，生物製品領域預計將快速擴張，並可能在預測期內收購痛風療法推動市場增長。

監管機構不斷增加的產品批准預計將推動痛風治療市場的增長。製造商正在採用收購與合作以及新產品開發策略來挖掘大部分患者群體未滿足的需求。

目前正在開發新藥，例如阿鹵芬酸鹽，它假定靶向腎尿酸轉運蛋白，主要是 URAT1 和 OAT4，以用作降尿酸劑。此外，降尿酸藥物用作痛風性關節炎的對症治療、一線藥物或聯合治療。

與抗痛風藥物相關的副作用可能會阻礙市場增長

根據美國食品和藥物管理局 (FDA) 的數據，用於治療痛風的處方藥在過去 8 年中因有時會出現嚴重的副作用而在美國造成 10 人死亡。秋水仙鹼是一種廣泛用於治療痛風的強效抗炎藥，已使用近 40 年，使其成為痛風患者一線治療的可用選擇之一。據FDA統計，共有17種秋水仙鹼產品獲得許可，每年全國銷售約3800萬片秋水仙鹼片劑。然而，從 2011 年到今年 8 月，FDA 收到了 353 份報告表明該藥物有副作用，其中大多數是腎功能或肝功能受損的患者，估計有 10 人死亡。我在這裡。腎或肝功能受損的人，或同時服用其他慢性病藥物的人，可能會因秋水仙鹼而出現嚴重的副作用。

此外，可使用皮質類固醇（如潑尼松）來減輕疼痛和炎症。這些藥物會增加血糖和血壓並引起情緒變化。副作用可能包括噁心、腹瀉和嘔吐。在日本、歐洲和美國，已有患者在使用苯溴馬隆時死於腎功能衰竭的報導。由於副作用，醫生傾向於為患有腎臟或肝臟問題的人開較低劑量的秋水仙鹼。因此，藥物副作用等因素可能會抑制市場增長。

行業分析

全球痛風治療市場根據波特五力、監管分析、供應鏈分析、定價分析、管道、未滿足的需求和流行病學等各種行業因素對市場進行了深入分析。 .

COVID-19 影響分析

預計 COVID-19 的爆發將在預測期內影響痛風治療市場的增長。根據 CreakyJoints 的說法，到 2020 年 5 月，痛風患者可能被認為屬於潛在的 COVID-19 並發症的高危人群。世界各地的冠狀病毒 (COVID-19) 大流行和封鎖正在影響各行各業公司的財務狀況。私營醫療保健部門也是受 COVID-19 大流行嚴重影響的部門之一。

隨著 COVID-19 大流行的持續，幾家公司正在測試治療它的藥物。例如，製藥商 Glenmark Pharmaceuticals 表示，2020 年 6 月 22 日，抗病毒藥物 favipiravir (Fabiflu) 被批准用於治療輕度至中度 COVID-19 患者，並在一周內實現全面商業化。印度藥品監管局已批准該抗病毒藥物用於“限制性緊急使用”用於輕度至中度病例，這些病例佔 COVID-19 感染的大部分。

一項隨機、開放標籤的研究表明，用於治療痛風和風濕性疾病的抗炎藥秋水仙鹼可能是治療 COVID-19 的有前景的藥物。 GRECCO-19 試驗（Greek Study on the Effects of Colchicine in the Effects of COVID-19 Complications Prevention）隨機分配了 105 名 COVID-19 患者接受標準治療或標準治療加秋水仙鹼治療 3 週，共納入 19 名患者。結果表明，秋水仙鹼治療組縮短了臨床惡化的時間，儘管在心臟或炎症生物標誌物方面沒有顯著的組間差異。

本報告提供了大約 45 多個市場數據表、40 多個圖表和 180 頁有關全球痛風藥物市場的信息。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 擴大生物製劑的採用
      • 增加與再生醫學相關的研發
    • 約束因素
      • 與抗痛風藥物相關的副作用
    • 商機
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 監管分析
  • 供應鏈分析
  • 定價分析
  • 管道分析
  • 未滿足的需求
  • 流行病學

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按藥物類別

  • 非甾體抗炎藥 (NSAID)
    • 布洛芬
    • □普生
    • 消炎痛
    • 塞來昔布
    • 其他
  • 高尿酸血症藥（降尿酸藥）
    • 黃嘌呤氧化□抑製劑
      • 別嘌醇（洛普林、齊羅普林）
      • 非布司他（尿酸）
    • 降尿酸藥
      • 苯溴馬隆
      • 丙磺舒
      • 磺□酮
    • 尿酸□
      • 果膠□
      • 拉布立克□
  • 腎上腺皮質類固醇
    • 地塞米松（Dexpak）
    • 甲潑尼龍（Medrol）
    • 潑尼松龍（Omnipread）
    • 潑尼松 (Raios)
    • 曲安西龍（Aristospan）
  • 秋水仙鹼
    • 科爾克裡斯
    • 緩解
  • 其他

第 8 章按應用程序

  • 急性痛風
  • 慢性痛風

第 9 章，最終用戶

  • 醫院藥房
  • 藥店
  • 在線頻道
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 治療分類基準
  • 值得關注的重點公司列表

第 12 章公司簡介

  • 諾華國際公司
    • 公司概況
    • 藥物類別組合和說明
    • 主要亮點
    • 財務摘要
  • GlaxoSmithKline PLC
  • Lannett Company, Inc
  • Mylan NV
  • Boehringer Ingelheim
  • Horizon Therapeutics plc
  • Regeneron Pharmaceuticals
  • Takeda Pharmaceutical Company Ltd
  • Teijin Pharma Ltd
  • Romeg Therapeutics, LLC

第 13 章全球痛風藥物市場-DataM

簡介目錄
Product Code: DMPH2562

Market Overview

Gout Therapeutics Market size was valued US$ 1.9 billion in 2021 and is estimated to reach US$ 4.1 billion by 2029, growing at a CAGR of 8.2% during the forecast period (2022-2029).

Gout is a type of inflammatory arthritis caused by the overabundance of uric acid in the body, either producing too much or excreting too little. Gout can be acute and chronic. Acute gout mostly affects the major extremity joint, with the small joints of the hands and feet the most affected. In chronic gout, hard swellings (known as tophi) can form on the joints made of uric acid and grow large, even breaking through the skin. The global gout therapeutics market is impacted by several factors such as the rising prevalence of gout globally due to changes in lifestyle, increasing alcohol consumption, increasing obesity & kidney diseases, high purine diet, and several medications diuretics.

Market Dynamics

The global gout therapeutics market growth is driven by the rising prevalence of gout globally due to changes in lifestyle, increasing alcohol consumption, increasing obesity & kidney diseases, high purine diet, and several medications diuretics are among the key factors driving the market growth.

Growing adoption of biologics and increasing R&D on regenerative medicines are expected to drive the global gout therapeutics market during the forecast period.

The major factors driving the growth of the market are the rising adoption of biologics and increasing R&D on regenerative medicines, technological advancements in imaging modalities improved. This condition can be treated or prevented with the use of drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate-lowering agents.

Biologics have witnessed rapid adoption and are replacing NSAIDs and corticosteroids owing to better results. Hence, the biologics segment is anticipated to expand at a rapid pace and is likely to gain gout therapeutics which drive the market growth in the forecast period.

Increasing product approvals by regulatory authorities are expected to drive the growth of the gout disease treatment market. Manufacturers are adopting acquisition & collaboration and new product development strategies to tap the unmet needs of a large proportion of the patient pool.

The new medication is being developed, such as arhalofenate, which is estimated to target renal transporters of uric acid, primarily URAT1 and OAT4, acting as uricosuric agents. Moreover, urate-lowering drugs are utilized for the symptomatic treatment of gout arthritis, as a first line of therapy or in combination therapy.

Side effects associated with gout therapeutics are likely to hinder the market growth

A prescription medicine used to treat gout is suspected to have caused 10 deaths in the U.S over the past eight years due to side effects that can sometimes be severe, according to the Food and Drug Administration (FDA). Colchicine, a strong anti-inflammatory that is widely used to treat gout, has been used for nearly 40 years and is one of the available options for the frontline treatment of people with gout. A total of 17 colchicine products have been licensed by the FDA and about 38 million colchicine tablets are sold in the nation each year, the FDA said. However, from 2011 to August this year, the FDA received 353 reports suggesting adverse reactions to the drug, mostly among patients with renal and liver dysfunction, with 10 deaths believed to be linked to the problem. People with renal or hepatic impairment and those who also take other drugs for chronic diseases could experience serious side effects from colchicine.

In addition, corticosteroids, such as prednisone, can be prescribed to reduce pain and inflammation. They can increase blood sugar levels and blood pressure and may induce mood changes. Side effects can include nausea, diarrhea and vomiting. In Japan, Europe and the US, there have been reports of patients dying of renal failure after using benzbromarone, because of the side effects, doctors tend to prescribe low-dose colchicine for people with renal or hepatic impairment. Thus, factors such as the adverse effects of the drugs may restrain the market growth.

Industry Analysis

The global gout therapeutics market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis, pricing analysis, pipeline, unmet needs, epidemiology.

COVID-19 Impact Analysis

The Covid - 19 pandemic is expected to impact the growth of the gout therapeutics market over the forecast period. According to CreakyJoints, in May 2020, people with gout may be considered in a higher-risk group for potential COVID-19 complications. The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one of the sectors, which has been majorly impacted by the COVID-19 pandemic.

With the ongoing COVID-19 pandemic, several companies are testing their drugs for their treatment. For instance, on June 22nd, 2020, the anti-viral drug Favipiravir (Fabiflu) was approved for the treatment of mild to moderate COVID-19 patients and will be commercialized full scale in a week, says drugmaker Glenmark Pharmaceuticals. The Drug Controller General of India approved the anti-viral for 'restricted emergency use' for treatment of mild to moderate cases, which accounts for a majority of COVID-19 infections.

Colchicine, an anti-inflammatory drug used to treat gout and rheumatic disease, may be a promising treatment for COVID-19, a randomized, open-label trial suggests. In the Greek Study on the Effects of Colchicine in COVID-19 Complications Prevention (GRECCO-19), investigators randomly assigned 105 patients who had COVID-19 to receive either the standard of care or the standard of care plus colchicine for 3 weeks. They found that for patients in the colchicine group, the time to clinical deterioration improved, although there were no significant differences between the groups in cardiac and inflammatory biomarkers.

Segment Analysis

The non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to hold the largest market share in global gout therapeutics market

The non-steroidal anti-inflammatory drugs (NSAIDs) are estimated to dominate the market, owing to the availability of these drugs at a lower cost compared to other drugs, high level of penetration of drugs, and the ability to relieve pain in case of an acute gout attack.

NSAIDs are the first-line drugs used to decrease the inflammation and the associated pain of rheumatic and non-rheumatic diseases. The rising number of gout patients, low cost of drugs, and application in combination therapy is likely to drive the market Indomethacin and naproxen are the major choice for the acute attack of gout.

NSAIDs decrease pain and swelling. Some NSAIDs are available over-the-counter, like ibuprofen and naproxen sodium. Stronger NSAIDs like indomethacin and celecoxib are prescribed by the doctor. Although NSAID effects on pain tend to be patient-specific, naproxen and indomethacin are common choices. Use of concomitant gastric protection with misoprostol or consideration of a cyclooxygenase-2 (COX-2)-specific NSAID might be considered if the patient has gastrointestinal (GI) risk or is older than 51 years.

To control the attack as quickly and safely as possible (recalling that it takes 5 half-lives to reach a steady state), NSAIDs with a short half-life (eg, ketoprofen, ibuprofen, or diclofenac) are preferred.

Geographical Analysis

North America region holds the largest market share in the global gout therapeutics market

North America is dominating the global gout therapeutics market, accounting for the largest market share, owing to the large presence of major players, high demand for gout therapy, and high cost of branded pharmaceuticals U.S. Also, the research and development of new drugs for gout treatment is expected to show dominance over the forecast period. In June 2020, Pharma major Dr. Reddy's Laboratories launched the generic Colchicine caused to prevent and treat acute gout flares in the US market.

The Asia Pacific region is expected to grow at the fastest growth rate over the forecast period owing to the diversified patient pool, and growing investment by major players with local manufacturers, and hospital chains in growing countries such as India, China, South Korea, and other South Asian countries. According to the Australian Institute of Health and Welfare report 2022, in 2017-2018, gout cost the Australian health system an estimated USD 196.5 million, representing 1.4% of disease expenditure on musculoskeletal conditions and 0.2% of total disease expenditure. Besides, changing lifestyles with a rising prevalence of smoking & alcohol consumption is expected to boost gout incidence over the period.

In December 2022, Selecta Biosciences, Inc., a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, completed the patient enrollment in the six-month, head-to-head, Phase 2 COMPARE clinical trial. The trial evaluates the superiority of a once-monthly dose of Selecta's lead product candidate, SEL-212 (ImmTOR + pegadricase), versus a bi-weekly dose of pegloticase, the current FDA-approved uricase therapy for adult patients with chronic refractory gout.

Demand for effective therapeutics for gout treatment is increasing. Numerous pipeline products and recent approvals of drugs to treat gout arthritis are expected to drive the market in the region. According to estimates more than 2 million people in the U.S. take medication to decrease serum uric acid levels. However, factors such as increasing competition in the generic sector, patent expiry of blockbuster products, and the high cost of the newly launched drugs are likely to hinder the growth of the market in the United States.

The Public Health Agency of Canada (PHAC), in collaboration with all Canadian provinces and territories, conducts national surveillance of gout and supports public health action.

Competitive Landscape

The global market for gout therapeutics is fragmented and highly competitive and consists of several major players. Few major players dominate the market share, and few emerging companies are expected to enter the market over the forecast period. Some of the market's major players market is Horizon Therapeutics plc, Lannett Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Ltd, and Mylan. The key players are adopting various growth strategies such as product launches, acquisitions, and collaborations, contributing to the global market's growth globally. For instance, On March 2nd, 2020, Avion Pharmaceuticals launched Gloperba (colchicine) oral solution for prophylaxis of gout flares in adults.

Companies are entering into collaborations, acquisitions, mergers, approvals and licensing for increasing their market penetration. In January 2020, US-based Novadoz Pharmaceuticals received FDA approval for their generic version of Febuxostat 40mg and 80mg tablets. The approved product is AB-rated to the brand Uloric, marketed by Takeda Pharmaceuticals America, Inc.

Key Companies to Watch

Novartis AG:

Overview: Novartis AG develops, manufactures, and markets healthcare products. The company mainly operates through three business segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of the cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics.

Product Portfolio:

Canakinumab: Canakinumab is a fully human monoclonal antibody targeting IL 1b that has an expanding list of clinical indications. Novartis' canakinumab, an IL-1B inhibitor, has shown remarkable clinical success in treating gout.

Key Developments: In Jun 2022, Novartis announced the approval of Cosentyx by the European Commission (EC). It is used for treatment of juvenile idiopathic arthritis (JIA) a category of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) in patients ages 6 years or older.

The global gout therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. Growing adoption of biologics
      • 4.1.1.2. Increasing R&D on regenerative medicines
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with gout therapeutics
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. Epidemiology

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
    • 7.1.2. Market Attractiveness Index, By Drug Class Segment
  • 7.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Ibuprofen
    • 7.2.4. Naproxen
    • 7.2.5. Indomethacin
    • 7.2.6. Celecoxib
    • 7.2.7. Others
  • 7.3. Anti-hyperuricemic Agents (Urate-Lowering Drugs)
    • 7.3.1. Xanthine oxidase inhibitors
      • 7.3.1.1. Allopurinol (Lopurin, Zyloprim)
      • 7.3.1.2. Febuxostat (Uloric)
    • 7.3.2. Uricosuric Medications
      • 7.3.2.1. Benzbromarone
      • 7.3.2.2. Probenecid
      • 7.3.2.3. Sulfinpyrazone
    • 7.3.3. Uricases
      • 7.3.3.1. Pegloticase
      • 7.3.3.2. Rasburicase
  • 7.4. Corticosteroids
    • 7.4.1. Dexamethasone (DexPak)
    • 7.4.2. Methylprednisolone (Medrol)
    • 7.4.3. Prednisolone (Omnipred)
    • 7.4.4. Prednisone (Rayos)
    • 7.4.5. Triamcinolone (Aristospan)
  • 7.5. Colchicine
    • 7.5.1. Colcrys
    • 7.5.2. Mitigare
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Acute Gout
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Chronic Gout

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospital Pharmacies
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Drug Stores
  • 9.4. Online Channels
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Drug Class Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Novartis International AG
    • 12.1.1. Company Overview
    • 12.1.2. Drug Class Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GlaxoSmithKline PLC
  • 12.3. Lannett Company, Inc
  • 12.4. Mylan NV
  • 12.5. Boehringer Ingelheim
  • 12.6. Horizon Therapeutics plc
  • 12.7. Regeneron Pharmaceuticals
  • 12.8. Takeda Pharmaceutical Company Ltd
  • 12.9. Teijin Pharma Ltd
  • 12.10. Romeg Therapeutics, LLC

LIST NOT EXHAUSTIVE

13. Global Gout Therapeutics Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Application
  • 13.3. Contact Us